

# Rethinking Gallbladder Health: Superfluous Organ or Vital Structure in Human Health?

---



**Presenter: Amie Skilton**  
**Naturopath, Nutritionist**  
**and Educator**  
Host: Linda Dal Molin



# Presenter | Amie Skilton

---



Amie Skilton's professional journey spans nearly two decades as a functional medicine practitioner and educator in naturopathic medicine. Her expertise has brought her to conference stages, television, and digital platforms, where she has addressed a broad audience that includes functional medicine practitioners and the general public. Amie's approach deeply integrates environmental factors with traditional health practices, emphasising the significance of a harmonious relationship between individuals and their surroundings for optimal health.

In 2017, Amie's personal health journey took a significant turn when she was diagnosed with Chronic Inflammatory Response Syndrome (CIRS), a condition often associated with mould exposure. This diagnosis transformed her health perspective and led her to become a certified Mould Testing Technician. Amie's experience with CIRS has greatly influenced her practice, emphasising the built environment's impact on health. Thus, she has expanded her clinical focus to include environmental health hazards alongside conventional naturopathic treatments.

# Our Host | Linda Dal Molin

---



Linda Dal Molin is the Director of Sales and Education for Designs for Health Australia.

Linda has a Masters in Human Nutrition, Bachelor of Health Science (Complementary Medicine), Advanced Diploma Naturopathy. She has been a practitioner for 25 years and worked in the natural health space for 27 years.

Linda has developed a strong relationship with the Designs for Health practitioner community. She will moderate the Q&A discussion with Steven in this webinar and engage our live Designs for Health practitioner community to bring insight and practical clinical pearls for all.



# Outline

---

- Overview of detoxification
- Gallbladder dysfunction
- Causes of gallbladder dysfunction
- Gallbladder support


# Outline

---

- **Overview of detoxification**
  - The gastrointestinal tract
  - Phases of liver detoxification (plus the gallbladder)
  - Bowels
  - Kidneys
  - Breath
  - Sweat

# GI tract and detoxification

- 20-25% of the detoxification activities actually takes place in the gut mucosa – the microvilli themselves carry out a significant amount of detoxification through the production of CYP450 enzymes.
- CYP3A and CYP2C represent the major intestinal CYPs, accounting for approximately 80% and 18%, respectively.<sup>1</sup>
- GI inflammation downregulates phase 2 activity in the liver.<sup>2</sup>



# GI tract and gallbladder health

---

- Gut microbiota causally influences cholelithiasis and may be related to bile salt hydrolases<sup>3</sup>:
  - *Clostridium senegalense*, *Coprococcus*, and *Lentisphaerae* increased the risk of cholelithiasis and expressed more bile salt hydrolases
  - *Holdemania*, *Lachnospiraceae* UCG010, and *Ruminococcaceae* NK4A214 weakly expressed bile salt hydrolases and were implied to have a protective effect against cholelithiasis
- A large number of studies showed that the diversity of intestinal flora in patients with gallstones especially *Firmicutes* is reduced<sup>4</sup>
- *Desulfovibrionales* considered gallstone-promoting microbiota<sup>5</sup>



# GI tract and gallbladder health

---

“Pathogenic microflora of the oral cavity (through mechanisms of immunomodulation) can affect the motility of the gallbladder and the expression of mucin genes (MUC1, Muc3, MUC4), and represent one of the promoters of stone formation in the gallbladder”<sup>6</sup>



# GI tract and gallbladder health

---

There appears to be a significant alteration of the GI microbiome in cholelithiasis patients, and the GI microbiome is involved in the pathogenesis of cholelithiasis through several pathways<sup>7</sup>:

- Biliary microbiome induces gallstone formation by regulating bile acid metabolism;
- *Helicobacter* species induce gallstone formation by precipitating calcium;
- LPS upregulates mucins via the tumor necrosis factor- $\alpha$  converting enzyme/transforming growth factor- $\alpha$ /epidermal growth factor receptor pathway and the EP4/p38MAPK pathway; GUS and PL accelerate precipitation of calcium bilirubinate.

# GI tract


---

## Post cholecystectomy:


- Reduced microbiota diversity, a decrease in the potentially beneficial genus *Faecalibacterium*, and an increase in the opportunistic pathogen *Escherichia/Shigella*;<sup>8</sup>
  - post-cholecystectomy diarrhoea (PCD) is highly prevalent among outpatients with cholecystectomy, and gut microbiota alteration is correlated with it due to bile acids in the colon - stimulates colonic 5-HT and increases colon motility;<sup>9,10</sup>
- Cholecystectomy eliminated ageing-associated faecal commensal microbiota;<sup>11</sup>
- Absent intestinal bacteria, such as *Bacteroides*, were negatively related to secondary bile acids and may be a leading cause of colorectal cancer incidence in cholecystectomy patient.<sup>11</sup>

Bile acids are also well known to modulate intestinal and colonic motility, but until recently the underlying mechanisms were poorly understood. Bile acids inhibit gastric emptying and reduce small intestinal transit time but stimulate colonic peristalsis and increase colonic transit time.<sup>12</sup>

# Liver detoxification – overview




# Liver detoxification – Phase I






# Liver detoxification – Phase II

## Phase II Pathways



# Liver detoxification – Phase III



# Gallbladder

---

## Bile<sup>13</sup>

- Bile is involved in the digestion of complex foods, in particular those containing high amounts of fat; it acts as a surfactant, helping fat emulsion by forming micelles, due to the amphipathic nature of the bile salts, thus making it easier for pancreatic lipases to hydrolyse triglycerides; micelles are also water soluble, thus facilitating absorption by the small intestine.
- It's the primary secretion of the liver – producing up to 800 mL per day.
- It is mainly composed of water (97–98%), but also contains bile salts (0.7%), bilirubin (0.2%), fats (0.51%; predominantly cholesterol, but also fatty acids and lecithin), and 200 meq/L of inorganic salts.
- Bile pigments are waste products generated by the degradation of old red blood cells; they include bilirubin, a yellow dye, and biliverdin, an oxidised form of bilirubin with a green colour.

# Gallbladder

---

- Bile sludge is when bile becomes thick and viscous and congests inside the gallbladder. The sludge is a collection of mucus and particulate solids—usually cholesterol crystals, calcium bilirubinate, and calcium salts.<sup>14</sup>
- When bile becomes too thick, it can alter gallbladder contractibility. While bile sludge often clears up on its own, in many cases, it can linger for some time, resulting in digestive-related concerns.<sup>14,15</sup>
- In one study following more than 100 patients with bile sludge for 21 months, almost 25% developed more significant liver/gallbladder concerns.<sup>15</sup>



# Gallbladder

---

## Gallbladder microflora<sup>16</sup>:

- in the biliary microecosystem, the main bacterial phyla were represented by *Firmicutes*, *Bacteroidetes*, *Actinobacteria*, and *Proteobacteria* and significant differences in the relative abundance of different taxa were found in the control group (no record of hepatobiliary disorder) vs individuals suffering from lithiasis.
- *Propionibacteriaceae* were more abundant in bile samples from control subjects.
- in patients with cholelithiasis members of the families *Bacteroidaceae*, *Prevotellaceae*, *Porphyromonadaceae*, and *Veillonellaceae* were more frequently detected.

# Kidneys

---

- CYP 450 enzyme activity occurs here also.
- Phase III detox occurs here – pH dependant (alkalise urine for max results).
- In a single pass 20% of renal blood flow is filtered by the glomeruli of the nephrons.
- The risk of kidney cancer is particularly high in the first 6 months after cholecystectomy and in patients who underwent a cholecystectomy before the age of 40 years (Kharazmi, 2023).



# Breath

---

- Our lungs move up to 10,000 litres of air per day and robust CYP450 enzyme activity occurs here also:
  - CYP2A13 is mainly expressed in the respiratory tract and plays an important role in metabolic activation of tobacco-derived nitrosamines.<sup>17</sup>
- Laparoscopic cholecystectomy (vs open cholecystectomy) seems to be associated with small but sustained alterations in the control of breathing and mechanics, which might have an unfavourable clinical impact on patients with compromised lung function.<sup>18</sup>
- Ethanol and methanol are eliminated via the breath.<sup>19</sup>

# Breath

---

Detection of poisoning by substances other than drugs: a neglected art.<sup>20</sup>

Breath odour	Likely poisons
Bitter almonds	Cyanide
Garlic	Malathion, parathion, arsenic, phosphorus, tellurium
Alcohol	Phenols, alcohols
Ethereal (sweet)	Ether
Stale tobacco	Nicotine
Acetone / penetrating	Lacquer
Coal gas	Carbon monoxide
Acrid	Paraldehyde
Phenolic (disinfectants)	Creosotes, phenols
Shoe polish	Nitrobenzene
Pears	Chloral



# Skin and sweat

---

The skin also acts as an excretory organ; it's estimated that 3-4 million eccrine sweat glands (collectively weighing about the same as one kidney – 100g) are distributed over almost the entire human body surface, and:

- An individual can perspire as much as several litres per hour and approximately 10 litres per day.<sup>21</sup>
- Water-soluble exogenous and endogenous toxic/bioactive substances, such as metals<sup>21</sup> including arsenic/cadmium/lead/mercury/nickel/copper<sup>22,23</sup>, pharmaceutical drugs<sup>24</sup>, cocaine and heroin<sup>25</sup>, BPA<sup>26</sup>, cytokines<sup>27</sup>, and steroids<sup>28</sup> can be eliminated in the sweat.
- Sweat has been analysed for approximately 120 various compounds, including toxic elements, and found that many toxic elements appeared to be preferentially excreted through sweat.<sup>29</sup>
  - Some xenobiotics that are rarely excreted in the urine without being metabolised, but can be excreted in the sweat e.g. excess nicotinamide cannot be eliminated through urine because of its reabsorption by the renal tubules, but it can be effectively excreted by the sweat gland.<sup>30</sup>

# Outline

---

- **Gallbladder dysfunction**
  - Signs of dysfunction
  - Symptoms of dysfunction
  - Pathology markers of dysfunction – blood test
  - Pathology markers of dysfunction – stool analysis

# GB dysfunction – symptoms

---

Clinical symptoms of cholestasis include jaundice, dark urine, and pruritis, as well as steatorrhea and fat and micronutrient malabsorption.

- Intolerance to fatty foods i.e. nausea.
- Light or clay coloured stools.
- Stools that float, appear frothy or foamy, and are foul smelling.
- An oily sheen on surface of toilet bowl.
- Symptoms of essential fatty acid deficiency.




# GB dysfunction – symptoms

---

## Pain<sup>31</sup>:

- RUQ or epigastric tenderness;
  - may be nocturnal or post-prandial;
- Typically episodic, can be mild to severe;
- Referred pain to top of right shoulder;
- May also experience posterior pain just below the right should blade.





# GB dysfunction – signs

---

## Jaundice:

- If a gallstone passes out of the gallbladder into the bile duct and blocks the flow of bile.
- Symptoms of jaundice include yellowing of the skin and whites of the eyes.





# GB dysfunction – signs

---

## Lipoma:

- These can be a result of trauma or genetic abnormalities but may also be related to obesity, alcohol abuse, **liver disease**, as well as glucose intolerance<sup>32</sup>;
- The prevalence of hepatic lipoma is closely related to lipid metabolism disorders, such as dyslipidemia and nonalcoholic fatty liver disease (NAFLD).<sup>33</sup>



# GB dysfunction – signs

---

## Pinguecula:<sup>34</sup>

- A yellowish to brown (sometimes white) protruding lesion in the conjunctiva that is easily seen on the nasal and temporal sides of the cornea;
- Development is affected by a number of intrinsic and extrinsic factors including patient's age and levels of sun, wind, and dust exposure however are associated with p53 mutation and increased cholesterol metabolism.



# GB dysfunction – signs

---

## Xanthelasma:

- Fatty yellowish bumps of cholesterol deposits around eyes\* and often represents an underlying disorder of lipid metabolism;<sup>35</sup>
- Is a sign of hyperlipidemia and is closely linked to atherosclerosis;<sup>36</sup>
- Primary biliary cirrhosis (PBC) is associated with xanthelasma and xanthomata.<sup>37</sup>



# GB dysfunction – signs

---

## Arcus senilis<sup>38,39</sup>:

- Develops as a white-grey ring from deposits of lipids near the sclero-corneal margin;
- Commonly found in the elderly but associated with hypercholesterolemia in <40-45 years.






# GB dysfunction – signs

## TCM gallbladder (GB) meridian channels<sup>40</sup>:

- Skin eruptions, rashes, or irritation along these meridians may indicate GB issues;
- Headaches on any of the GB points may indicate liver/GB origin.



The Internal and External Qi Flow of the Gall Bladder (GB) Channels



# GB dysfunction – signs

---

## TCM gallbladder (GB) meridian channels<sup>40</sup>:

- Skin eruptions, rashes, or irritation along these meridians may indicate GB issues.
- Headaches on any of the GB points may indicate liver/GB origin.



# GB dysfunction – blood markers

---

## Clinical Features of Gallstone-Related Diseases <sup>41</sup>

### Biliary Colic

H&P: Severe, episodic, epigastric or RUQ pain; may be nocturnal, occasionally postprandial.  
+/- RUQ tenderness.

Labs: No leukocytosis; normal total bilirubin and amylase/lipase.

Imaging: RUQ ultrasound indicating cholelithiasis *without* findings of cholecystitis ([Table 3](#)).

### Acute Cholecystitis

H&P: +/- fever; symptoms persist or worsening; positive for RUQ tenderness.

Labs: Leukocytosis is common. Total bilirubin is usually normal to mildly elevated (<2.0 mg/dL), unless there is concomitant choledocholithiasis. Amylase and lipase are usually normal unless there is concomitant pancreatitis.

Imaging:

- RUQ ultrasound, see [Table 3](#). The diagnosis of cholecystitis is NOT made based on ultrasound findings alone. Diagnosis is determined based on the clinical findings above, in combination with consistent ultrasound findings.
- HIDA (only indicated if RUQ ultrasound is inconclusive, or contradicts the clinical impression) demonstrates lack of gallbladder filling.

# GB dysfunction – blood markers

## Clinical Features of Gallstone-Related Diseases<sup>41</sup>

Cholelithiasis	<p><u>H&amp;P:</u> Biliary pain, jaundice, no fever.</p> <p><u>Labs:</u> Elevated bilirubin (total bilirubin often &gt;2.0 mg/dL). Amylase/lipase are usually normal, unless there is concomitant pancreatitis.</p> <p><u>Imaging:</u> RUQ ultrasound shows CBD dilation (&gt;7 mm).<sup>**</sup></p>
Cholangitis	<p><u>H&amp;P:</u> Jaundice, often febrile, RUQ tenderness.</p> <p><u>Labs:</u> Elevated bilirubin (total bilirubin &gt;2.0 mg/dL), leukocytosis. Amylase/lipase are usually normal to mildly elevated, unless there is concomitant pancreatitis.</p> <p><u>Imaging:</u> RUQ ultrasound: CBD dilation (&gt;7 mm).<sup>**</sup></p>
Gallstone Pancreatitis	<p><u>H&amp;P:</u> +/- jaundice, +/- fever, epigastric tenderness.</p> <p><u>Labs:</u> Normal or elevated bilirubin, elevated amylase and/or lipase to typically 3× upper limit of normal. Elevated ALT &gt;150 suggests a biliary cause of pancreatitis, based on meta-analysis<sup>1</sup></p> <p><u>Imaging:</u> RUQ ultrasound: Cholelithiasis and biliary dilation variably present. Note: RUQ ultrasound is often limited for the evaluation of the pancreatic parenchyma.</p> <p><u>Absence of other common causes of pancreatitis:</u> Ethanol abuse, hyperglycemia, hypertriglyceridemia, hypercalcemia, or medications known to cause pancreatitis.</p>

# GB dysfunction – blood markers

---

## Cholesterol<sup>42</sup>:

- Thickened bile is the hallmark of biliary stasis and may occur if total cholesterol is increased  $>5.69$  mmol/L – it may be the only finding on the them screen so watch for other signs/symptoms.
- If total cholesterol is increased  $>5.69$  mmol/L, LDL is  $>3.1$  mmol/L, triglyceride levels are increased  $>1.24$  mmol/L, and HLD levels are decreased  $< 1.42$  mmol/L then early development of fatty liver is possible.
- Liver congestion might also be indicated is ALT is below 10 as well.

# GB dysfunction – blood markers

---

## Bilirubin<sup>42</sup>:

- Increased total bilirubin levels are associated with a dysfunction or blockage of the liver, gallbladder, or biliary tree, or red blood cell hemolysis.
- Total bilirubin is composed of two forms of bilirubin:
  - Indirect (unconjugated) bilirubin, which circulates in the blood on its way to the liver bound to albumin – elevated levels are usually associated with increased RBC destruction; and
  - Direct (conjugated) bilirubin, which is the form of bilirubin made water-soluble before it is excreted in the bile – an increase associated with dysfunction in liver/gallbladder/biliary tree.
  - Fasting can cause false elevation.



# GB dysfunction – blood markers

---

- **Elevated SGOT/AST<sup>42</sup>**: optimal 10-30 U/L, >30 is an issue associated with liver dysfunction (p130), >100 is alarming – indicates dysfunction outside liver and biliary tree.
- **Elevated ALP<sup>42,43</sup>**: ALP is an important indicator of cholestasis and hepatobiliary diseases in humans. Serum ALP levels can be elevated by cholestatic or infiltrative diseases of the liver and by diseases causing obstruction to the biliary system.

# GB dysfunction – blood markers

---

## Elevated gamma glutamic transferase (GGTP)<sup>42</sup>:

- Present in highest amounts in liver cells, to a lesser extent kidney, prostate and pancreas – also found in biliary tract epithelial cells;
- Liberated following cell damage and/or biliary obstruction:
  - If GGTP is increased above ALT and AST issue is likely outside of liver but inside biliary tree (gall bladder, common bile duct and pancreas);
  - Increased GGTP (often 5 times higher than normal) PLUS increased ALP indicates biliary tree obstruction.

# GB dysfunction – blood markers

---

## Elevated gamma glutamic transferase (GGTP)<sup>42</sup>:

- If GGTP >30 and ALP >100 with normal or increased AST (>30) and ALT (>30) biliary obstruction is probable;
- Biliary obstruction with possible caclui becomes more likely with increased total bilirubin (>20.5 umol/dL) and direct bilirubin (>3.4 umol/dL).

# GB dysfunction – stool markers

---

## Steatocrit:

- Elevated steatocrit indicates an increased amount of fat in the faeces, suggesting that the body is not properly absorbing fats from the diet resulting in steatorrhea;
- Stools may be light-coloured, greasy, smelly, frothy/foamy, floating, hard to flush;
- This generally results from pancreatic exocrine insufficiency but can also occur as a symptom of various underlying gastrointestinal disorders, such celiac disease, Crohn's disease, or **issues affecting the liver, gallbladder or bile ducts (i.e. primary biliary cirrhosis)**, or medications that inhibit fat absorption such as orlistat.

# GB dysfunction – stool markers

---

## Elastase-1<sup>44</sup>:

- Pancreatic elastase 1 (PE1) is a proteolytic enzyme secreted exclusively by the human pancreas, and as such, it reflects overall pancreatic exocrine function Lowered elastase-1;
- The pancreatic elastase 1 faecal test is used to diagnose insufficiencies of the pancreas that may be a result of cystic fibrosis, chronic pancreatitis, pancreatic cancer, inflammatory bowel disease, **gallstones**, T1D, or Shwachman-Diamond syndrome.

Normal: >200 ug elastase/gram faecal matter

Moderate pancreatic insufficiency: 100-200 ug elastase/gram faecal matter

Severe pancreatic insufficiency: <100 ug elastase/gram faecal matter



# GB dysfunction – stool markers

---

## Betaglucuronidase (b-glucuronidase):

- High fat, high protein and low fibre diets are associated with higher b-glucuronidase activity compared to vegetarian or high soluble fibre diets;
- Higher b-glucuronidase may be associated with an imbalanced intestinal microbiota profile;
- Bacterial b-glucuronidase (bBG) appears to be an etiologic factor in pigment gallstone disease as it deconjugates conjugated bilirubin to form calcium bilirubinate gallstone<sup>45</sup>;
  - Increase in the activity of human biliary beta-glucuronidase (hBG) may be a secondary response, developed after bile duct inflammation because it was elevated only when the bile duct obstruction was associated with infection<sup>46</sup>;
- A study on the microbiome of gallstones and bile in patients with cholelithiasis found that 30% of cultured strains from cholesterol gallstones secrete  $\beta$ -glucuronidase (and phospholipase A2)<sup>47</sup>;
  - *Pseudomonas spp.* were the dominant bacteria in the gallstones of cholesterol and bile and had the highest  $\beta$ -glucuronidase activity.

# Outline

---


- **Causes of gallbladder dysfunction**
  - Infections
  - Mycotoxins
  - Vitamin D deficiency
  - Dietary influences
  - Hormones
  - Circadian rhythm
  - ANS

# GB dysfunction – infections

---

## Bacterial infections<sup>48</sup>:

- Gastrointestinal tract flora, such as *E. coli*, *Klebsiella* spp., *Enterococci* spp., *Bacteroides* spp;
- Also *Serratia marcescens*.





# GB dysfunction – mycotoxins

---

## Mycotoxins:

- According to animal studies, mycotoxin poisoning can lead to multifocal hepatocyte necrosis in the liver, the gallbladder mucosa becomes inflamed due to hyperplasia and necrosis of the bile duct, which further cause the gallbladder to become brittle;
  - Chronic aflatoxin exposure leads to biliary retention, biliary ductular hyperplasia, fibrosis (aflatoxin is produced by *Aspergillus flavus* found in WDBs)<sup>49</sup>;
  - *Pithomyces chartarum* (also found in WDBs) causes damage to biliary tract, leads to obliterating cholangitis, and distorted fibrotic liver<sup>50</sup>;
- CIRS-WDB patients often present with low VIP (vasoactive intestinal polypeptide)
  - VIP is a potent stimulant of fluid and bicarbonate secretion from cholangiocytes via cAMP-independent pathways, suggesting that this neuropeptide plays a major regulatory role in biliary transport and secretion<sup>51</sup>.

# GB dysfunction – deficiencies

---

## Vitamin D deficiency:

- Vitamin D deficiency is suggested to be associated with gallbladder stasis<sup>52</sup>:
  - Low serum vitamin D level is associated with intrahepatic cholestasis of pregnancy<sup>53</sup>;
  - A role for vitamin D supplementation is thought to have potential to prevent gallstones in this special population;
  - Gallstones to be associated to low vitamin D exposure in utero and to renal failure suggesting that vitamin D might have an impact on gallstone disease<sup>54</sup>.



# GB dysfunction – dietary

---

## Dietary influences:

- Dietary fat has the strongest effect on emptying the gallbladder, which correlated with plasma CCK levels<sup>55</sup> – a low fat diet may result in reduced gallbladder emptying;
- A sedentary lifestyle and a diet rich in animal fats and refined sugars and poor in vegetable fats and fibres are significant risk factors for gallstone formation<sup>56</sup>;
- Rapid weight loss i.e. HCG diet, VLCD:
  - risk of symptomatic gallstones requiring hospitalisation or cholecystectomy, was 3-fold greater with VLCD than LCD<sup>57</sup>;
  - during active weight loss suggest that newly formed gallstones occur within 4 weeks and with incidence rates 15 to 25-fold higher than in the general obese population<sup>58</sup>.

# GB dysfunction – dietary

---

## Gluten consumption in those with celiac gene and/or celiac disease<sup>59,60,61</sup>:

- Prevalence of biliary stones in celiac patients may be higher compared to the normal population;
- Enteropathy in the proximal part of the small intestine reduces the release of cholecystokinin (CCK) from the duodenal enteroendocrine cells (is synthesised and secreted by I-cells from the proximal small intestine mucosal epithelium in response to a meal with fat and protein):
  - It also appears that an abnormality in the gall bladder response to endogenous cholecystokinetic hormones (cholecystokinin and motilin) might also be a factor [brown 1987];
- Perturbation of bile composition occurs; hepatic production of bile cholesterol, phospholipids, and bile salts, as well as bile flow, increased almost double in patients with CD compared with healthy individuals' bile cholesterol levels, and their bile is supersaturated accordingly;
- Gallbladder dysmotility develops, which mainly expresses with an impaired emptying during the digestive phase:
  - Reversible with a gluten-free diet in most cases.

# GB dysfunction – hormones

---

- Oestrogen increases the amount of cholesterol relative to bile salts and lecithin in bile, increasing the saturation of bile with cholesterol, which leads to cholesterol crystal formation<sup>62</sup>:
  - Excess of oestrogens can lead to decreased bile flow, toxic bile acid (BA) accumulation, subsequently causing intrahepatic cholestasis;
  - Oestrogen-induced cholestasis (EIC) may have increased incidence during pregnancy, and within women taking oral contraception and postmenopausal hormone replacement therapy, and result in liver injury, preterm birth, meconium-stained amniotic fluid, and intrauterine fetal death in pregnant women;
  - Impaired cell membrane fluidity, inflammatory responses and change of hepatocyte tight junctions are also involved in the pathogenesis of EIC;
- Oestrogens and oral contraceptives are both associated with several liver related complications including intrahepatic cholestasis, sinusoidal dilatation, peliosis hepatis, hepatic adenomas, hepatocellular carcinoma, hepatic venous thrombosis and an increased risk of gallstones.<sup>63</sup>

# GB dysfunction – circadian

---

## Melatonin:

- Plays a role in the modulation of biliary functions and liver damage in response to a number of insults - it inhibits cholangiocyte hyperplasia (it also appears to have hepatoprotective properties, may reduce fibrosis)<sup>64</sup>;
- Improves cholestatic liver disease via the gut-liver axis;
- Melatonin Prevents Pigment Gallstone Formation Induced by Bile Duct Ligation<sup>65</sup>;
- Melatonin helps in the recovery of gallbladder neuromuscular function during acute cholecystitis<sup>66</sup>;
- Due to its antioxidant activity, along with its effect on the aging gall bladder myocytes, inhibits gallstone formation<sup>67</sup>;

A clinical trial has validated the amelioration effects of bright-light therapy (BLT) on hepatogenic pruritus, potentially via restoring circadian rhythms through retino-thalamic pathway.<sup>68,69</sup>

# GB dysfunction – circadian

---

## Circadian rhythm:

- Plasma bile acids and key genes in bile acid biosynthesis are driven, in part, by hepatic molecular clock<sup>70</sup>;
  - Bile acid concentration (and corresponding genes) exhibit significant circadian rhythms and circadian oscillations are flattened and altered following by cholecystectomy<sup>71</sup>;
  - Eating outside of ideal feeding window associated with high biliary cholesterol content (and subsequent gallstone formation)<sup>72</sup>;
- Sun exposure and UVR load were associated with a decreased risk of primary biliary cholangitis.<sup>73</sup>



# Outline

---

- **Gallbladder support**
  - Manual therapies
  - Bitters and other herbs
  - Nutrients
  - Other interventions



# Manual therapies

---

## Coffee enema:

- Administration of coffee enemas stimulate bile excretion<sup>74</sup>;
- Doctors at the University of Minnesota showed that coffee enemas stimulate an enzyme system in the liver called glutathione S-transferase by 600-700% above normal activity levels.



# Manual therapies

---

## Castor oil packs:


- Preliminary evidence that castor oil packs may have a positive effect on normalising liver enzymes and cholesterol levels. and improving symptoms of constipation.<sup>75,76</sup>

# Manual therapies

---

## Acupuncture:

- Stimulation of Jianjing (GB 21) can effectively relieve shoulder-back pain and stomachache, and regulate the volume of the deflated and expanded gallbladder in cholecystitis patients.<sup>77</sup>



# Bitters foods and herbs

---

- Lemon juice – accelerates hepatobiliary excretion<sup>78</sup>;
- ACV – significantly decreases serum total cholesterol (along with fasting plasma glucose and HbA1C concentrations)<sup>79</sup>;
- Gentian – has been used in Chinese herbalism for over 2000 years as an excellent tonic for digestive system, work on stomach, liver and gall bladder<sup>80,81</sup>;
- Fruit and vegetables:
  - An inverse association between FV consumption and risk cholecystectomy in women (aged 48-60)<sup>82,83</sup>;
  - High intake of broccoli and cabbage was associated with a decreased risk of gallbladder cancer.<sup>84</sup>



# Bitters and other herbs

---

## Globe Artichoke

- The chlorogenic acids (cynarin and caffeoylquinic acid) support the healthy functioning of both phase one and two detoxification pathways in the liver;
- Considered a most potent choleric and cholagogue herbs available to practitioners. Effects on bile secretion occurs an hour after the administration of a single dose<sup>85</sup>:
  - the excretion of cholesterol and other solids, as well as increases in faecal bile salts have been shown in both pre- clinical and clinical studies – indicated for choleresis<sup>86</sup>;
- Increases glutathione peroxidase activity – hepatoprotective and hepatorestorative:
  - A trophorestorative herb that can protect the integrity of bile canalicular membrane from chemically induced distortions.

# Bitters and other herbs

---

## St. Mary's Thistle or Milk Thistle:

- Traditionally used in Western Herbal Medicine as a hepatoprotective:
  - Properties can be attributed to the flavonolignan compound silymarin. Research has suggested that standardisation to between 70-80% of this component is best to achieve therapeutic effects;
  - The term “silymarin” actually refers to 7 flavonolignan compounds: silybin A, silybin B, isosilybin A, isosilybin B, silychristin, isosilychristin, and silydianin. Some extracts may also contain the flavonoid taxifolin.
- Induces both phase one and two detoxification pathways – recoupling these phases.

# Bitters and other herbs

---

## St. Mary's Thistle or Milk Thistle

- The following functions that contribute to its activity in supporting liver health:<sup>85-89</sup>
  - Prevents uptake of toxins and pathogens by stabilisation of cell membranes. Silybinin and silymarin are incorporated into the outer cell membrane thereby altering its structure. In doing so, these compounds stabilise the membranes and regulate their permeability and subsequent intracellular contents. They prevent the penetration of toxins into the hepatocytes, providing a “toxin blockade”;
  - Aids hepatic repair and regeneration by enhancing ribosomal RNA synthesis (via stimulating nucleolar polymerase A) and cellular proliferation;
  - Improves intracellular glutathione concentration;
  - Increases the proliferation of Kupffer cells.

# Bitters and other herbs

---


- **Schisandra:** a warming TCM herb that supports and protects many aspects of liver function. Lignan components are considered a primary therapeutic compound and have been shown to support hepatic functions such as glycogen and protein synthesis, and enzymatic activity during both phase one and two detox pathways. They also support liver health by assisting the regeneration of hepatocytes and inhibiting lipid peroxidation in liver tissues.<sup>87,90</sup>
- **Rosemary:** a potent antioxidant that induces several enzymes involved in phase two pathways, helping to keep balance between the two detox systems.<sup>87</sup>
- **Beetroot:** contains betaine and betanin which impart supportive effects on both liver health and function (reducing fatty infiltration of hepatocytes, improving glutathione status, supporting phase one and two detox pathways, thinning the bile and supporting gall bladder function).<sup>91-94</sup>

# Nutrients

---

Lipotropic nutrients are useful to promote the flow of bile from the liver:

- Choline
- Taurine
- Methionine
- B6, B9, B12





# Nutrients

---

- Magnesium sulphate (MgSO<sub>4</sub>):
  - oral administration of MgSO<sub>4</sub> has a significant effect on Gallbladder volume with maximum effect at 1 and 2 hours after medication.<sup>95</sup>
- Calcium saccharate (calcium d-glucarate):
  - Enhances liver function through phase 2 glucuronidation pathways - downregulates hepatocyte apoptosis and reduces ROS production;<sup>96</sup>
  - Inhibits b-glucoronidase.<sup>97</sup>

# Other interventions

---

## Fibre:

- Decreases stool transit time;
- Acts to sequester conjugated xenobiotics and endobiotics located in the bile;
- Reduces the level of bacterial deconjugating enzymes in the stool;
  - Slippery elm: soluble fibre, contains mucilage, forms a gel-like layer, demulcent effect;
  - Inulin: prebiotic fibre, fermented by colonic bacteria for fuel, enhances bioavailability of minerals.

# Other interventions

---

## Essential oils:

- Peppermint oil and caraway oil show a relaxing effect on the gall-bladder.<sup>98</sup>
- In the 70's an approach to dissolving gallstones using natural medicines called terpenes was reported in several journals.<sup>99</sup> Such an approach has not gained wide acceptance, however, probably because the formula is not readily available. The predominant terpene in this formula is menthol, so essential oil of peppermint in capsule form may have a comparable effect. This use of peppermint is theoretical; no studies using peppermint oil to dissolve gallstones have been performed.

# References

---

1. Thelen K, Dressman JB. Cytochrome P450-mediated metabolism in the human gut wall. *Journal of Pharmacy and Pharmacology* 2009. 61: 541-558. <https://doi.org/10.1211/jpp.61.05.0002>
2. Gelberg H. Pathophysiological Mechanisms of Gastrointestinal Toxicity. *Comprehensive Toxicology*. 2018:139–78. doi: 10.1016/B978-0-12-801238-3.10923-7. Epub 2017. PMID: PMC7173509.
3. Liu X, Qi X, Han R, et al. Gut microbiota causally affects cholelithiasis: a two-sample Mendelian randomization study. *Frontiers in Cellular and Infection Microbiology*. Vol 13 (2023).
4. Huang Xiaoyu, Yang Yi, Li Xueli, Zhu Xiaoya, Lin Dan, Ma Yueran, Zhou Min, Cui Xiangyi, Zhang Bingyu, Dang Dongmei, Lü Yuhong, Yue Changwu. The gut microbiota: A new perspective for tertiary prevention of hepatobiliary and gallbladder diseases. *Frontiers in Nutrition* 2023.
5. Hu H, Shao W, Liu Q et al. Gut microbiota promotes cholesterol gallstone formation by modulating bile acid composition and biliary cholesterol secretion. *Nat Commun* 13, 252 (2022).
6. Grigor'eva IN, Romanova TI. Gallstone Disease and Microbiome. *Microorganisms*. 2020;8(6):835.
7. Dan WY, Yang YS, Peng LH, Sun G, Wang ZK. Gastrointestinal microbiome and cholelithiasis: Current status and perspectives. *World J Gastroenterol*. 2023;29(10):1589-1601.
8. Frost F, Kacprowski T, Rühlemann M et al. Carrying asymptomatic gallstones is not associated with changes in intestinal microbiota composition and diversity but cholecystectomy with significant dysbiosis. *Sci Rep* 11, 6677 (2021). <https://doi.org/10.1038/s41598-021-86247-6>
9. Xu Y, Wang J, Wu X, et al. Gut microbiota alteration after cholecystectomy contributes to post-cholecystectomy diarrhea via bile acids stimulating colonic serotonin. *Gut Microbes* 2023, 15(1). <https://doi.org/10.1080/19490976.2023.2168101>
10. Li YD, Liu BN, Zhao SH, et al. Changes in gut microbiota composition and diversity associated with post-cholecystectomy diarrhea. *World J Gastroenterol*. 2021;27(5):391-403. doi: 10.3748/wjg.v27.i5.391.
11. Wang W, Wang J, Li J, et al. Cholecystectomy Damages Aging-Associated Intestinal Microbiota Construction. *Frontiers in Microbiology* 2018;Vol 9. DOI=10.3389/fmicb.2018.01402.
12. Ticho AL, Malhotra P, Dudeja PK, et al. Bile Acid Receptors and Gastrointestinal Functions. *Liver Res*. 2019;3(1):31-39. doi: 10.1016/j.livres.2019.01.001.
13. Abril AG, Villa TG, Sánchez-Pérez Á, et al. The Role of the Gallbladder, the Intestinal Barrier and the Gut Microbiota in the Development of Food Allergies and Other Disorders. *International Journal of Molecular Sciences*. 2022; 23(22):14333. <https://doi.org/10.3390/ijms232214333>

# References

---

14. Pazzi P, Gamberini S, Buldrini P, et al. Biliary sludge: the sluggish gallbladder. *Dig Liver Dis.* 2003;35 Suppl 3:S39-45. doi: 10.1016/s1590-8658(03)00093-8.
15. Hill PA, Harris RD. Clinical Importance and Natural History of Biliary Sludge in Outpatients. *J Ultrasound Med.* 2016;35(3):605-10. doi: 10.7863/ultra.15.05026.
16. Molinero N, Ruiz L, Milani C, et al. The human gallbladder microbiome is related to the physiological state and the biliary metabolic profile. *Microbiome* 7, 100 (2019). <https://doi.org/10.1186/s40168-019-0712-8>.
17. Anttila S, Raunio H, Hakkola J. Cytochrome P450–Mediated Pulmonary Metabolism of Carcinogens Regulation and Cross-Talk in Lung Carcinogenesis. *American Journal of Respiratory Cell and Molecular Biology.* Volume 44, Issue 5. <https://doi.org/10.1165/rcmb.2010-0189RT>.
18. Bablekos GD, Michaelides SA, Roussou T, et al. Changes in Breathing Control and Mechanics After Laparoscopic vs Open Cholecystectomy. *Arch Surg.* 2006;141(1):16–22. doi:10.1001/archsurg.141.1.16.
19. Caravati EM, Anderson KT. Breath alcohol analyzer mistakes methanol poisoning for alcohol intoxication. *Ann Emerg Med.* 2010;55(2):198-200. doi: 10.1016/j.annemergmed.2009.07.021.
20. Badcock NR. Detection of poisoning by substances other than drugs: a neglected art. *Ann Clin Biochem* 2000; 37: 146±157.
21. Sato K. The physiology, pharmacology, and biochemistry of the eccrine sweat gland. *Rev Physiol Biochem Pharmacol.* 1977;79:51–131. doi: 10.1007/BFb0037089.
22. Sears ME, Kerr KJ, Bray RI. Arsenic, cadmium, lead, and mercury in sweat: a systematic review. *J Environ Public Health.* 2012;2012:184745.
23. Kuan WH, Chen YL, Liu CL. Excretion of Ni, Pb, Cu, As, and Hg in Sweat under Two Sweating Conditions. *Int J Environ Res Public Health.* 2022;19(7):4323. doi: 10.3390/ijerph19074323.
24. Johnson HL, Maibach HI. Drug excretion in human eccrine sweat. *J Invest Dermatol.* 1971;56:182–188. doi: 10.1111/1523-1747.ep12260784.
25. Cone EJ, Hillsgrove MJ, Jenkins AJ, et al. Darwin, Sweat Testing for Heroin, Cocaine, and Metabolites, *Journal of Analytical Toxicology* 1994; Vol 18, Issue 6, p298–305. <https://doi.org/10.1093/jat/18.6.298>.



# References

---

26. Genuis SJ, Beesoon S, Birkholz D, et al. Human excretion of bisphenol A: blood, urine, and sweat (BUS) study. *J Environ Public Health*. 2012;2012:185731. doi: 10.1155/2012/185731.
27. Cizza G, Marques AH, Eskandari F, et al. POWER Study Group. Elevated neuroimmune biomarkers in sweat patches and plasma of premenopausal women with major depressive disorder in remission: the POWER study. *Biol Psychiatry*. 2008;64:907–911. doi: 10.1016/j.biopsych.2008.05.035.
28. Takemura T, Wertz PW, Sato K. Free fatty acids and sterols in human eccrine sweat. *Br J Dermatol*. 1989;120:43–47. doi: 10.1111/j.1365-2133.1989.tb07764.x
29. Genuis SJ, Birkholz D, Rodushkin I, Beesoon S. Blood, urine, and sweat (BUS) study: monitoring and elimination of bioaccumulated toxic elements. *Arch Environ Contam Toxicol*. 2011;61:344–357. doi: 10.1007/s00244-010-9611-5.
30. Zhou SS, Li D, Sun WP, et al. Nicotinamide overload may play a role in the development of type 2 diabetes. *World J Gastroenterol*. 2009;15:5674–5684. doi: 10.3748/wjg.15.5674.
31. Napolitano LM, Alam HB, Biesterveld BE, et al. Evaluation and Management of Gallstone-Related Diseases in Non-Pregnant Adults [Internet]. Ann Arbor (MI): Michigan Medicine University of Michigan; 2021
32. Charifa A, Azmat CE, Badri T. Lipoma Pathology. [Updated 2022 Dec 5]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK482343/>
33. Miller E.R., Fowler M.E. *Fowler's Zoo and Wild Animal Medicine*. Volume 8 Elsevier Health Sciences; Amsterdam, The Netherlands: 2014.
34. Kim TH, Chun YS, Kim JC. The pathologic characteristics of pingueculae on autofluorescence images. *Korean J Ophthalmol*. 2013;27(6):416-20. doi: 10.3341/kjo.2013.27.6.416.
35. Harris J, Cao S, Hile G, et al. Diffuse xanthomas in a patient with primary biliary cholangitis and lipoprotein X. *JAAD Case Rep*. 2020;7:30-32. doi: 10.1016/j.jdc.2020.10.029.
36. Chen HW, Lin JC, Wu YH, et al. Risk of Non-Alcoholic Fatty Liver Disease in Xanthelasma Palpebrarum. *J Inflamm Res*. 2021;14:1891-1899. doi: 10.2147/JIR.S305694.

# References

---

37. Macías-Rodríguez RU, Torre-Delgadillo A. Xanthelasma and xanthomas striatum palmare in primary biliary cirrhosis. *Annals of Hepatology (AoH)* 2006; Vol. 5. Issue 1. p49. DOI: 10.1016/S1665-2681(19)32040-X
38. Murthy K, Prasad M, Prasad M, et al. EYE: “A clue to diagnosis”. *BJMP* 2015;8(2):a817
39. Rallidis LS, Iordanidis D, Iliodromitis E. The value of physical signs in identifying patients with familial hypercholesterolemia in the era of genetic testing. *Journal of Cardiology* 2020; <https://doi.org/10.1016/j.jcc.2020.07.005>.
40. Huang WL. “Can Autoimmune Hepatitis Be Treated Without the Use of Corticosteroids and Immunosuppressive Drugs?”. *Acta Scientific Medical Sciences* 3.7 (2019): 178-186.
41. Napolitano LM, Alam HB, Biesterveld BE, et al. Evaluation and Management of Gallstone-Related Diseases in Non-Pregnant Adults [Internet]. Ann Arbor (MI): Michigan Medicine University of Michigan; 2021. Table 1, Clinical Features of Gallstone-Related Diseases. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK569245/tab>
42. Weatherby D, Ferguson S. *Blood Chemistry and CBC Analysis : Clinical Laboratory Testing from a Functional Perspective*. Bear Mountain Pub.; 2002. P20.
43. ALP: Green R.M., Flamm S. AGA technical review on the evaluation of liver chemistry tests. *Gastroenterology*. 2002;123:1367–1384. doi: 10.1053/gast.2002.36061.
44. Lam KW, Leeds J. How to manage: patient with a low faecal elastase. *Frontline Gastroenterol*. 2019;12(1):67-73. doi: 10.1136/flgastro-2018-101171.
45. Skar V, Skar AG, Bratlie J, et al. Beta-glucuronidase activity in the bile of gallstone patients both with and without duodenal diverticula. *Scand J Gastroenterol*. 1989;24(2):205-12. doi: 10.3109/00365528909093038.
46. Chen CY, Shiesh SC, Tsao HC, et al. Human biliary beta-glucuronidase activity before and after relief of bile duct obstruction: is it the major role in the formation of pigment gallstones? *J Gastroenterol Hepatol*. 2000;15(9):1071-5. doi: 10.1046/j.1440-1746.2000.02292.x.
47. Peng Y, Yang Y, Liu Y, et al. Cholesterol gallstones and bile host diverse bacterial communities with potential to promote the formation of gallstones. *Microb. Pathog*. 2015, 83–84, 57–63.

# References

---

48. Prakash Kumari Pilli, H., & Payala, V. (2022). Infections of Biliary Tract. IntechOpen. doi: 10.5772/intechopen.100063
49. Al Hallak M, Verdier T, Bertron A, et al. Fungal Contamination of Building Materials and the Aerosolization of Particles and Toxins in Indoor Air and Their Associated Risks to Health: A Review. *Toxins*. 2023; 15(3):175. <https://doi.org/10.3390/toxins15030175>
50. Park JH, Cox-Ganser JM, Kreiss K, et al. Hydrophilic fungi and ergosterol associated with respiratory illness in a water-damaged building. *Environ Health Perspect*. 2008 Jan;116(1):45-50. doi: 10.1289/ehp.10355.
51. Cho, Won Kyoo, Boyer JL. "Vasoactive intestinal polypeptide is a potent regulator of bile secretion from rat cholangiocytes." *Gastroenterology* 117 2 (1999): 420-8 .
52. Onal ED, Berker D, Guler S. Vitamin D Deficiency and Gallbladder Stasis. *Dig Dis Sci*. 2015;60(12):3823-4. doi: 10.1007/s10620-015-3901-8.
53. Gençosmanoğlu Türkmen G, Vural Yılmaz Z, Dağlar K, et al. Low serum vitamin D level is associated with intrahepatic cholestasis of pregnancy. *J Obstet Gynaecol Res*. 2018;44(9):1712-1718. doi: 10.1111/jog.13693.
54. Shabanzadeh DM, Jørgensen T, Linneberg A, et al. Vitamin D and gallstone disease—A population-based study 2016; *Endocrine* 54(3). DOI: 10.1007/s12020-016-1113-4
55. Marciani L, Cox E, Hoad C, et al. Effects of various food ingredients on gall bladder emptying. *Eur J Clin Nutr* 67, 1182–1187 (2013). <https://doi.org/10.1038/ejcn.2013.168>
56. Misciagna G, Centonze S, Leoci C, et al. Diet, physical activity, and gallstones—a population-based, case-control study in southern Italy. *The American Journal of Clinical Nutrition* 1999. Volume 69, Issue 1, p120-126. <https://doi.org/10.1093/ajcn/69.1.120>.
57. Johansson K, Sundström J, Marcus C. et al. Risk of symptomatic gallstones and cholecystectomy after a very-low-calorie diet or low-calorie diet in a commercial weight loss program: 1-year matched cohort study. *Int J Obes* 38, 279–284 (2014). <https://doi.org/10.1038/ijo.2013.83>
58. Weinsier RL, Ullmann DO. Gallstone formation and weight loss. *Obes Res*. 1993;1(1):51-6. doi: 10.1002/j.1550-8528.1993.tb00008.x.
59. Shateri K, Shabestari FH, Pashaei MR. Gallstone Frequency in Adults With Celiac Disease: Results of a Population-Based Celiac Disease Registry From West Azerbaijan, IRAN. *Dis Diagn*. 2022; 11(1):14-18
60. Poddighe D, Dossybayeva K, Abdukhakimova D, et al. Celiac Disease and Gallbladder: Pathophysiological Aspects and Clinical Issues. *Nutrients*. 2022;14(20):4379. doi: 10.3390/nu14204379.

# References

---

61. Brown A, Bradshaw M, Richardson R et al. Pathogenesis of the impaired gallbladder contraction of celiac-disease. *Gut* 1987. 28. 1426-32. 10.1136/gut.28.11.1426.
62. Zu Y, Yang J, Zhang C, et al. The Pathological Mechanisms of Estrogen-Induced Cholestasis: Current Perspectives. *Front Pharmacol.* 2021;12:761255. doi: 10.3389/fphar.2021.761255.
63. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Estrogens and Oral Contraceptives. [Updated 2020 May 28]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK548539/>
64. Glaser S, Han Y, Francis H, Alpini G. Melatonin regulation of biliary functions. *Hepatobiliary Surg Nutr* 2013;3(1):35-43. doi: 10.3978/j.issn.2304-3881.2013.10.04
65. hu-Chu Shiesh, Chiung-Yu Chen, Xi-Zhang Lin, et al. Melatonin Prevents Pigment Gallstone Formation Induced by Bile Duct Ligation in Guinea Pigs, *Hepatology* 2000. Vol 32, Issue 3, p455-460. <https://doi.org/10.1053/jhep.2000.16332>.
66. Gomez-Pinilla PJ, Camello PJ, Pozo MJ. *Journal of Pharmacology and Experimental Therapeutics* 2007; 323 (1) 138-146; DOI: <https://doi.org/10.1124/jpet.107.123240>
67. Koppiseti S, Jenigiri B, Terron MP et al. Reactive Oxygen Species and the Hypomotility of the Gall Bladder as Targets for the Treatment of Gallstones with Melatonin: A Review. *Dig Dis Sci* 53, 2592–2603 (2008). <https://doi.org/10.1007/s10620-007-0195-5>
68. Bergasa NV, Link MJ, Keogh M, et al. Pilot study of bright-light therapy reflected toward the eyes for the pruritus of chronic liver disease. *Am J Gastroenterol.* 2001;96:1563–70.
69. Beuers U, Wolters F, Oude Elferink RPJ. Mechanisms of pruritus in cholestasis: understanding and treating the itch. *Nat Rev Gastroenterol Hepatol.* 2023;20:26–36.
70. Eggink HM, Oosterman JE, de Goede, P, et al. Complex interaction between circadian rhythm and diet on bile acid homeostasis in male rats. *Chronobiology International* 2017; 34(10), 1339–1353. <https://doi.org/10.1080/07420528.2017.1363226>
71. Zhang F, Duan Y, Xi L, et al. The influences of cholecystectomy on the circadian rhythms of bile acids as well as the enterohepatic transporters and enzymes systems in mice. *Chronobiol Int.* 2018;35(5):673-690. doi: 10.1080/07420528.2018.
72. He C, Shen W, Chen C, et al. Circadian Rhythm Disruption Influenced Hepatic Lipid Metabolism, Gut Microbiota and Promoted Cholesterol Gallstone Formation in Mice. *Front Endocrinol (Lausanne).* 2021;12:723918. doi: 10.3389/fendo.2021.723918.
73. French J, Simpson-Yap S, Ng J, et al. Pre-onset sun exposure significantly associated with risk of primary biliary cirrhosis, *International Journal of Epidemiology* 2021; Volume 50, Issue Supplement\_1, dyab168.610, <https://doi.org/10.1093/ije/dyab168.610>

# References

---

74. Kim ES, Chun HJ, Keum B, et al. Coffee enema for preparation for small bowel video capsule endoscopy: a pilot study. *Clin Nutr Res*. 2014;3(2):134-41. doi: 10.7762/cnr.2014.3.2.134.
75. Keaton D, Myatt D. Effects of castor oil on lymphocytes subsets. Presented at: AANP Conference; September 2 – 6, 1992; The Buttes, Tempe Arizona.
76. Arslan GG, Eser I. An examination of the effect of castor oil packs on constipation in the elderly. *Complement Ther Clin Pract*. 2011; 17: 58-62.
77. Wen FY, Li SC, Wang GM, et al. Effects of acupuncture of Jianjing (GB 21) on gallbladder volume and symptoms of cholecystitis patients. *Zhen Ci Yan Jiu*. 2012;37(5):398-402. Chinese.
78. Cherng SC, Chen YH, Lee MS, et al. Acceleration of hepatobiliary excretion by lemon juice on 99mTc-tetrofosmin cardiac SPECT. *Nucl Med Commun*. 2006;27(11):859-64. doi: 10.1097/01.mnm.0000243377.57001.33.
79. Hadi A, Pourmasoumi M, Najafgholizadeh A, et al. The effect of apple cider vinegar on lipid profiles and glycemic parameters: a systematic review and meta-analysis of randomized clinical trials. *BMC Complement Med Ther*. 2021;21(1):179. doi: 10.1186/s12906-021-03351-w.
80. Darshan S, Doreswamy R. Patented antiinflammatory plant drug development from traditional medicine. *Phytotherapy Res*. 2004;18(5):343–357.
81. Mirzaee F, Hosseini A, Jouybari HB, et al. Medicinal, biological and phytochemical properties of *Gentiana* species. *J Tradit Complement Med*. 2017;7:400–8. doi: 10.1016/j.jtcme.2016.12.013. doi
82. Nordenvall C, Oskarsson V, Wolk A. Fruit and vegetable consumption and risk of cholecystectomy: a prospective cohort study of women and men. *Eur J Nutr*. 2018;57(1):75-81. doi: 10.1007/s00394-016-1298-6.
83. Tsai CJ, Leitzmann MF, Willett WC, et al. Fruit and Vegetable Consumption and Risk of Cholecystectomy in Women. *The American Journal of Medicine* 2006; Vol 119, Issue 9, p760-767. <https://doi.org/10.1016/j.amjmed.2006.02.040>.
84. Ren HG, Luu HN, Liu Y, et al. High intake of cruciferous vegetables reduces the risk of gastrointestinal cancers: results from observational studies. *Crit Rev Food Sci Nutr*. 2023;1-7. doi: 10.1080/10408398.2023.2271070.



# References

---

85. Braun, L. & Cohen, M. "Herbs and Natural Supplements: An Evidence Based Guide" Ed. 4, Vol 2. 2015, Elsevier, Australia
86. Bone, K. & Mills, S. "Principles and Practice of Phytotherapy: Modern Herbal Medicine" Ed. 2, 2015, Churchill Livingstone Elsevier, Great Britain
87. Hechtman, L. "Clinical Naturopathic Medicine" Second Ed. 2019, Elsevier, Chatswood, Australia
88. Hodges, R. E. and Minich, D. M. "Modulation of Metabolic Detoxification Pathways Using Foods and Food-Derived Components: A Scientific Review with Clinical Application" J Nutr. Metab., 2015 doi: 10.1155/2015/760689
89. "Milk Thistle Fruit" Excerpt from Expanded Commission E Monographs © 2023 (<https://www.herbalgram.org/resources/expanded-commission-e/milk-thistle-fruit/>)
90. Bone, K. "Clinical Applications of Ayurvedic and Chinese Herbs. Monographs for the Western Herbal Practitioner" 1996, Phytotherapy Press, QLD, Australia
91. Srivastava, S. et. al. "Beetroot supplementation on non-alcoholic fatty liver disease patients" Current Research in Nutrition & Food Science, 2019; 7(1), 96-101. doi: <http://dx.doi.org/10.12944/CRNFSJ.7.1.10>.
92. Albasher G, et. al. "Ameliorative Effect of Beta vulgaris Root Extract on Chlorpyrifos-Induced Oxidative Stress, Inflammation and Liver Injury in Rats" Biomolecules. 2019;9(7):261. doi:10.3390/biom9070261.
93. Krajka-Kuźniak, V. et. al. "Beetroot juice protects against N-nitrosodiethylamine-induced liver injury in rats" Food Chem Toxicol. 2012; Jun;50(6):2027-33. doi: 10.1016/j.fct.2012.03.062.
94. Krajka-Kuźniak, V. et. al. "Betanin, a beetroot component, induces nuclear factor erythroid-2-related factor 2-mediated expression of detoxifying/antioxidant enzymes in human liver cell lines" Br J Nutr. 2013; 110(12):2138-49. doi: 10.1017/S0
95. Obideen, Kamil M.D.; Wehbi, Mohammad M.D.; Shaukat, Aasma M.D.; Cai, Qiang M.D.\*. THE EFFECT OF MAGNESIUM SULFATE ON THE HUMAN GALLBLADDER: 140. American Journal of Gastroenterology 99():p S47, October 2004.
96. Ayyadurai VAS, Deonikar P, Fields C. Mechanistic Understanding of D-Glucaric Acid to Support Liver Detoxification Essential to Muscle Health Using a Computational Systems Biology Approach. Nutrients. 2023 Feb 1;15(3):733. doi: 10.3390/nu15030733. PMID: 36771439; PMCID: PMC9921405.
97. Calcium-D-glucarate. Altern Med Rev. 2002 Aug;7(4):336-9. PMID: 12197785.
98. Goerg KJ, Spilker T. Effect of peppermint oil and caraway oil on gastrointestinal motility in healthy volunteers: a pharmacodynamic study using simultaneous determination of gastric and gall-bladder emptying and oro-caecal transit time. Aliment Pharmacol Ther. 2003 Feb;17(3):445-51. doi: 10.1046/j.1365-2036.2003.01421.x. PMID: 12562459.
99. Minnesota Medicine 1971; 54:649-651; British Medical Journal 1979; 278:24

# THANK YOU





[designsforhealth.com.au](https://designsforhealth.com.au)